Rochem International Inc Rochem International Inc

X
[{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,250.0 million","upfrontCash":"$25.0 million","newsHeadline":"Lilly and MiNA Therapeutics Announce saRNA Research Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$1,316.0 million","upfrontCash":"$16.0 million","newsHeadline":"Silence Therapeutics and Hansoh Pharma Announce Collaboration to Develop Therapeutics Leveraging Silence\u2019s mRNAi GOLD\u2122 Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"SRI International","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SRI International Announces Collaboration Agreement with Janssen","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"AbSci","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$610.0 million","newsHeadline":"Absci Announces Research Collaboration with Merck","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"BigHat Biosciences","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BigHat Biosciences Completes First Stage of Research Collaboration with Amgen","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Prellis Biologics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prellis Biologics Announces Collaboration and License Agreement with Bristol Myers Squibb","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Artisan Industries Inc.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience Signs Collaboration with Artisan Bio to Engineer Next Generation Cell Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Discovery"},{"orgOrder":0,"company":"Gandeeva Therapeutics","sponsor":"Lux Capital","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Gandeeva Raises $40M in Series A Funding to Develop Novel Therapies Based on Precision Imaging of Protein-Drug Interactions","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Abcam plc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Abcam Collaborates With Twist Bioscience to Enhance Antibody Discovery for Diagnostic and Research Applications","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Eighteen Fifty-Nine","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"1859 Inc. Launches with $40 Million Series A to Industrialize New Medicine Discovery by Combining Artificial Intelligence and Empirical Screening Data at Scale","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"i2o Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"i2O Therapeutics Announces Research Collaboration and Option Agreement with Janssen to Investigate the Oral Delivery of Macromolecules","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Undisclosed"},{"orgOrder":0,"company":"Excelra","sponsor":"X-Chem","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"X-Chem and Excelra's GOSTAR Join Forces to Advance Drug Discovery for Challenging Targets","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"INDIA","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"WuXi AppTec Inc.","sponsor":"Orbit Discovery","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Orbit Discovery and WuXi AppTec Sign Agreement to Access Peptide Discovery and Optimisation Technologies","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"CHINA","productType":"Peptide","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Specifica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Specifica Is Pleased to Announce the United States Patent and Trademark Office Has Granted Two Patents to Specifica for Its Innovative Generation 3 Antibody Discovery Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Prellis Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Prellis Biologics Announces Collaboration with Sanofi","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"LifeMine Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$70.0 million","newsHeadline":"LifeMine Therapeutics and GSK Enter Drug Discovery and Development Alliance","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","amount":"$185.0 million","upfrontCash":"$25.0 million","newsHeadline":"Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE\u00ae Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Undisclosed"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Undisclosed"},{"orgOrder":0,"company":"VantAI","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$1,316.0 million","upfrontCash":"$16.0 million","newsHeadline":"Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Preclinical"},{"orgOrder":0,"company":"Apertura Gene Therapy","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","amount":"$67.0 million","upfrontCash":"Undisclosed","newsHeadline":"Apertura Gene Therapy Launches with $67M Series A Financing from Deerfield and an Innovative Technology Platform to Develop Genetic Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Discovery"},{"orgOrder":0,"company":"Acuitas","sponsor":"GC Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GC Biopharma Concludes Agreement With Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Undisclosed"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"A*STAR's Bioprocessing Technology Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi Advanced Therapies and A*STAR Announce Partnership to Advance Cell and Gene Therapy in The Asia-Pacific Region","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Undisclosed"},{"orgOrder":0,"company":"Empirico","sponsor":"AbCellera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Illumina","sponsor":"Deerfield Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Illumina and Deerfield Management Partner to Accelerate Drug Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery Platform"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR to Present its Axiomer RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Preclinical"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nimble Therapeutics Announces Achievement of Development Milestones From Multiple Partnered Programs Connected to a Strategic Large Pharma Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery"},{"orgOrder":0,"company":"Anagenex","sponsor":"Catalio","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Anagenex Closes $30 Million Series A Round led by Catalio to Advance Small Molecule Drug Discovery with a Novel, Directed Evolution Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Evotec","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec Enters a Drug Discovery Collaboration with Janssen","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"GERMANY","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"xFOREST Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Otsuka Enters Collaboration with xFOREST Therapeutics on RNA Structure- \nTargeted Drug Discovery Covering Multiple Diseases","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"JAPAN","productType":"Small molecule","productStatus":"Undisclosed","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Sanyou Biopharmaceuticals","sponsor":"Dragon Sail Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sanyou Biopharmaceuticals Forged Strategic Partnership with Dragon Sail Pharmaceutical to Upgrade Integrated Innovative Antibody Drug R&D","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Cronos Group","sponsor":"Geocann","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cronos Group Partners with Geocann to Leverage VESIsorb Delivery Technology for Faster Absorption","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Undisclosed"},{"orgOrder":0,"company":"Touchlight","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight Signs Patent License Agreement with Pfizer for The Use of dbDNA For the Manufacture of mRNA-Based Vaccines, Therapeutics and Gene Therapies","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Undisclosed"},{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ring Therapeutics Announces Three Presentations at the 41st Annual Meeting of the American Society for Virology (ASV)","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Discovery"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"LSA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector\u00ae Platform for CAR-T Therapy","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Undisclosed"},{"orgOrder":0,"company":"Kyowa Pharmaceutical Industry","sponsor":"Bora Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"KYOWA Pharmaceutical Industry Co. Ltd. Partners with Bora Pharmaceuticals to Manufacture Generic Product for Filing in Japan","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Undisclosed"},{"orgOrder":0,"company":"Thorne HealthTech","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Thorne HealthTech Announces Two-Year Collaboration with AstraZeneca on Disease Discovery System to Advance Novel Drug Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Starpharma","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Starpharma Signs New DEP Agreement With MSD","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"AUSTRALIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Undisclosed"},{"orgOrder":0,"company":"Prellis Biologics","sponsor":"Celesta Capital","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"X-Chem","sponsor":"BioDuro","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioDuro-Sundia and X\u2011Chem Enter Partnership to Launch DEL Services in China for the Discovery of New Small Molecule Drugs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Zerion Pharma","sponsor":"Hovione","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zerion Pharma and Hovione Extend Partnership to Cover Use of The Dispersome\u00ae Technology Platform in Nutraceuticals","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Preclinical"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Expands Partnership with Merck","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"ElevateBio","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Undisclosed"},{"orgOrder":0,"company":"OmniAb","sponsor":"Avista Public Acquisition Corp. II","pharmaFlowCategory":"D","amount":"$396.0 million","upfrontCash":"$130.0 million","newsHeadline":"Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Synaffix","sponsor":"Emergence Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$360.0 million","newsHeadline":"Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Preclinical"},{"orgOrder":0,"company":"Orbital Therapeutics","sponsor":"Beam Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Discovery"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Drive Capital","pharmaFlowCategory":"D","amount":"$90.0 million","upfrontCash":"Undisclosed","newsHeadline":"Forge Biologics Announces $90 Million Series C Financing to Expand Client Offerings and Add Services to Enhance End-to-End Gene Therapy Manufacturing Platforms","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Undisclosed"},{"orgOrder":0,"company":"GigaGen","sponsor":"Department of Defense","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Cytoreason","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"$20.0 million","newsHeadline":"Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"ISRAEL","productType":"Undisclosed","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"OliPass","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vanda Pharmaceuticals and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Preclinical"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"8VC","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"Undisclosed","newsHeadline":"Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Pantherna Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Circularis Biotechnologies","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ginkgo Bioworks Acquires Circularis to Strengthen Capabilities in Cell and Gene Therapy","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Charles River Launches nAAVigation Vector Platform to Accelerate Gene Therapy Programs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Illumina","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Illumina Launches Strategic Research Collaboration with AstraZeneca to Accelerate Drug Target Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery Platform"},{"orgOrder":0,"company":"aTyr Pharma","sponsor":"Dualsystems Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"aTyr Pharma Announces Research Collaboration with Dualsystems Biotech AG to Identify 10 New Therapeutic Targets","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prime Medicine Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Undisclosed"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Prime Medicine Announces Closing of Upsized Initial Public Offering","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Undisclosed"},{"orgOrder":0,"company":"VectorBuilder","sponsor":"Legend Capital","pharmaFlowCategory":"D","amount":"$56.1 million","upfrontCash":"Undisclosed","newsHeadline":"VectorBuilder Secures CNY410M in Series C Round","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"October 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Undisclosed"},{"orgOrder":0,"company":"XtalPi","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"XtalPi Announces Research Collaboration with Janssen","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"ProteoNic","sponsor":"GigaGen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ProteoNic Announces Broadening of Giga Gen's Rights To 2G UNic\u2122 Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Undisclosed"},{"orgOrder":0,"company":"OmniAb","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ligand Announces Completion of OmniAb Spin-Off","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"AbCellera","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera\u2019s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"WuXi Advanced Therapies","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"WuXi ATU Announces Licensing Agreement with Janssen for TESSA\u2122 Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Undisclosed"},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Salipro Biotech Enters Into Collaboration And License Agreement With Sanofi To Advance Discovery Programs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"SWEDEN","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery"},{"orgOrder":0,"company":"Metagenomi","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$80.0 million","newsHeadline":"Ionis Partners with Metagenomi to Add Gene Editing to Its Broad Technology Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Touchlight","sponsor":"Voyager Therapeutics, Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Touchlight Signs License Agreement With Voyager for Use of Touchlight\u2019s DNA Technology in Voyager\u2019s Capsid Discovery Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"Undisclosed","date":"November 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Beacon Discovery","sponsor":"Eurofins CDMO","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Eurofins Scientific Announces Acquisition of Beacon Discovery, Substantially Expanding Its Integrated Drug Discovery Capabilities and Expertise","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"SonoThera","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$60.7 million","upfrontCash":"Undisclosed","newsHeadline":"SonoThera Completes $60.75M Series A Funding for Ultrasound-Guided, Nonviral Gene Therapy Platform Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Undisclosed"},{"orgOrder":0,"company":"Entactbio","sponsor":"4BIO Capital","pharmaFlowCategory":"D","amount":"$81.0 million","upfrontCash":"Undisclosed","newsHeadline":"Entact Bio Launch with $81M Series A to Develop Precision Medicines for Targeted Protein Enhancement","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery"},{"orgOrder":0,"company":"Infinimmune","sponsor":"Playground Global","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Infinimmune Raises $12 Million in Seed Funding to Pioneer Novel Approach to Antibody Drug Discovery and Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nimble Therapeutics Delivers Lead Compounds for Two Programs Under Collaboration with Large Pharma Partner, Triggering Milestone Payments","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Preclinical"},{"orgOrder":0,"company":"Parallel Bio","sponsor":"Refactor Capital","pharmaFlowCategory":"D","amount":"$4.3 million","upfrontCash":"Undisclosed","newsHeadline":"Parallel Bio Secures $4.3 Million Seed Round to Accelerate Drug Discovery through Human Immune System in a Dish","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery"},{"orgOrder":0,"company":"Alteogen","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alteogen Enters Into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products Enabled by Alteogen\u2019s Hybrozyme\u2122 Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"SOUTH KOREA","productType":"Undisclosed","productStatus":"Biosimilar","date":"January 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery Platform"},{"orgOrder":0,"company":"OriCiro Genomics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"$85.0 million","upfrontCash":"Undisclosed","newsHeadline":"Moderna to Acquire OriCiro Genomics","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Belharra Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","amount":"$50.0 million","upfrontCash":"Undisclosed","newsHeadline":"Belharra Therapeutics Debuts With $130 Million in Funding","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Undisclosed"},{"orgOrder":0,"company":"Synaffix","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Enters License Agreement with Amgen to Build Next Generation ADCs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"IntoCell","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IntoCell Enters into Development and License Option Agreement with ADC Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Preclinical"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$1,120.0 million","upfrontCash":"$20.0 million","newsHeadline":"Nimble Therapeutics Announces Expansion of its Discovery and Development Partnership with Genentech","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Discovery"},{"orgOrder":0,"company":"Synaffix","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Preclinical"},{"orgOrder":0,"company":"Harbor Discoveries","sponsor":"Deerfield Management","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cold Spring Harbor Laboratory and Deerfield Management Launch Harbor Discoveries to Advance New Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Twist Bioscience and Astellas Enter into Multitarget Antibody Discovery Research Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"AskBio","sponsor":"ReCode Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"January 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Discovery Platform"},{"orgOrder":0,"company":"InstaDeep","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$688.0 million","upfrontCash":"$443.3 million","newsHeadline":"BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"National Resilience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Undisclosed"},{"orgOrder":0,"company":"MicrofluidX","sponsor":"CCRM","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Microfluidx And CCRM Partner On End-to-end Bioprocessing Of CAR-T Cell Therapies","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Discovery"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Cristal Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lonza Collaborates with Cristal Therapeutics and McSAF to Expand Bioconjugates Offering","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Cryoport Systems Inc","sponsor":"Syneos Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Neochromosome","sponsor":"Sumitovant Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Neochromosome and Sumitovant Biopharma Announce Successful Collaboration to Accelerate Protein Drug Discovery and Improve Manufacturing","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Lonza Group","sponsor":"McSAF","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lonza Collaborates Cristal Therapeutics And McSAF to Expand Bioconjugates Offering","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Atomic AI","sponsor":"Playground Global","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Atomic AI Launches with $35 Million Series A Financing to Advance AI-driven RNA Structure Platform for Treating Undruggable Diseases","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"X-Chem","sponsor":"Kymera Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"X-Chem and Kymera Expand Existing Partnership","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Generate Biomedicines","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$1,900.0 million","upfrontCash":"$50.0 million","newsHeadline":"Amgen and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$670.0 million","upfrontCash":"$20.0 million","newsHeadline":"Genesis Therapeutics Announces Strategic Collaboration with Lilly to Discover Novel Therapies Using the Genesis Molecular AI Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"May 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,280.0 million","upfrontCash":"$30.0 million","newsHeadline":"Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Proxygen","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"$554.0 million","upfrontCash":"Undisclosed","newsHeadline":"Proxygen announces strategic collaboration with Merck","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"AUSTRIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Atomwise","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,020.0 million","upfrontCash":"$20.0 million","newsHeadline":"Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,235.0 million","upfrontCash":"Undisclosed","newsHeadline":"PeptiDream Announces New Research and Collaboration Agreement with Lilly for the Discovery of Novel Peptide Drug Conjugates","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"JAPAN","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,221.5 million","upfrontCash":"Undisclosed","newsHeadline":"Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"HONG KONG","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery Platform"},{"orgOrder":0,"company":"PeptiDream","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2,100.0 million","upfrontCash":"Undisclosed","newsHeadline":"PeptiDream Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel Peptide Drug Conjugates","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"JAPAN","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Ratio Therapeutics","sponsor":"Duquesne Capital","pharmaFlowCategory":"D","amount":"$20.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ratio Therapeutics Announces $20M Series A Financing to Advance Targeted Radiotherapies for Cancer Treatment","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Synaffix","sponsor":"MacroGenics","pharmaFlowCategory":"D","amount":"$586.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaffix Inks $586m Deal with MacroGenics to Enable Next Generation ADCs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Generian Pharmaceuticals","sponsor":"Mitobridge","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Generian Achieves First Milestones in Mitobridge Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Bio Immunitas","sponsor":"GenScript ProBio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"A Joint Collaboration Between Bio Immunitas and GenScript ProBio Leads to the Development and Fast Track Manufacturing of A Novel Therapeutic Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Adimab","sponsor":"Ablexis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ablexis Announces License Agreement with Adimab","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Evotec","sponsor":"Related Sciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Related Sciences Expand Integrated Drug Discovery and Development Partnership","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"GERMANY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Merck Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Enters into Antibody Agreement with Merck","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Schrodinger","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$425.0 million","upfrontCash":"Undisclosed","newsHeadline":"Schr\u00f6dinger Hosts Platform Day","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Life Edit Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moderna And Life Edit Therapeutics Enter Strategic Collaboration To Accelerate The Development Of Novel In Vivo Gene Editing Therapies","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Luxna Biotech","sponsor":"Summit Pharmaceuticals Europe Srl","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Summit Pharmaceuticals International Corporation Invests in Luxna Biotech Co., Ltd. Possessing the Nucleic Acid Pharmaceutical Element Technologies","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Undisclosed"},{"orgOrder":0,"company":"TandemAI","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"TandemAI Raises $35 Million in Series A Financing to Expand Integrated Computational and Wet Lab Solutions to Accelerate Drug Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Chroma Medicine","sponsor":"Google Ventures","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology and Expand Pipeline of Durable Precision Genomic Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Preclinical"},{"orgOrder":0,"company":"Touchlight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Touchlight Announces First FDA Clearance of an IND Utilising Doggybone DNA","therapeuticArea":"Technology","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"IND Enabling"},{"orgOrder":0,"company":"Charles River Laboratories International","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Charles River and Flagship\u2019s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Kytopen","sponsor":"Mirus Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kytopen and Mirus Bio Announce Partnership to Unlock New and Scalable Genome Engineering Capabilities for the Next-Generation of Living Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Undisclosed"},{"orgOrder":0,"company":"Antiverse","sponsor":"InnoSpark","pharmaFlowCategory":"D","amount":"$3.0 million","upfrontCash":"Undisclosed","newsHeadline":"Antiverse Raises Funding and Demonstrates Therapeutic Antibody Identification With AI-driven Drug Discovery Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocytogen Announces RenLite\u00ae Licensing Agreement with Janssen","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"Alexandria Venture Investments","pharmaFlowCategory":"D","amount":"$86.5 million","upfrontCash":"Undisclosed","newsHeadline":"Ring Therapeutics Raises $86.5 Million in Series C Funding to Create Next Generation Programmable Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Preclinical"},{"orgOrder":0,"company":"AbCheck","sponsor":"Czech Republic","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Seamless Therapeutics","sponsor":"Wellington Partners","pharmaFlowCategory":"D","amount":"$12.5 million","upfrontCash":"Undisclosed","newsHeadline":"Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"CHARM Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Arzeda","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arzeda, the Protein Design Company\u2122, Announces Collaboration with Takeda to Accelerate Protein Biologics Optimization","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Undisclosed"},{"orgOrder":0,"company":"Generation Bio","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","amount":"$76.0 million","upfrontCash":"$40.0 million","newsHeadline":"Moderna and Generation Bio Announce Strategic Collaboration to Develop Non-Viral Genetic Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect\u2122","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Preclinical"},{"orgOrder":0,"company":"Proxygen","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$2,550.0 million","upfrontCash":"Undisclosed","newsHeadline":"Proxygen Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel Molecular Glue Degraders","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"AUSTRIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Veneno Technologies","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Veneno Technologies, a Novel DRP Drug Discovery Company, Has Entered Into a Joint Research Agreement with Astellas Pharma Inc.","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Discovery"},{"orgOrder":0,"company":"Eterna Therapeutics","sponsor":"Lincoln Park Capital","pharmaFlowCategory":"D","amount":"$10.0 million","upfrontCash":"Undisclosed","newsHeadline":"Eterna Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for Up To $10 Million","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Undisclosed"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Samsung Venture Investment Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Araris Biotech AG Announces Strategic Investment with Samsung Ventures","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Undisclosed"},{"orgOrder":0,"company":"Center for iPS Cell Research and Application","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CiRA, Kyoto University and Astellas Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Discovery"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Rubic One Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Veneno Technologies","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Veneno Technologies, a Novel DRP Drug Discovery Company, Announces Joint Research Agreement with Sumitomo Pharma Co. Ltd.","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Discovery"},{"orgOrder":0,"company":"3B Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$465.0 million","upfrontCash":"$40.0 million","newsHeadline":"3B Pharmaceuticals Enters Into a Global Exclusive Licensing Agreement for Its FAP-Targeting Peptide Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"GERMANY","productType":"Peptide","productStatus":"Undisclosed","date":"April 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Orbital Therapeutics","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"Orbital Therapeutics Secures $270 Million in Series A Financing to Unleash Full Potential of RNA Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Initial Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"With $75 Million from Apple Tree Partners, Initial Therapeutics Launches to Create a New Kind of Drug Designed to Stop the Formation of Difficult-to-Drug Protein Targets","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$1,280.0 million","upfrontCash":"$30.0 million","newsHeadline":"Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Cyclica","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$406.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ginkgo Bioworks Partners with Boehringer Ingelheim to Develop Breakthrough Therapies for Hard-to-Treat Diseases","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery"},{"orgOrder":0,"company":"Just \u2013 Evotec Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","amount":"$640.0 million","upfrontCash":"Undisclosed","newsHeadline":"Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Undisclosed","productStatus":"Biosimilar","date":"May 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Undisclosed"},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"DyNAbind","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Salipro Biotech and DyNAbind Announce Milestone Achievement in Collaboration to Enable DEL for Membrane Proteins","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNTech and Matinas End Oral mRNA Delivery Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Preclinical"},{"orgOrder":0,"company":"Thousand Oaks Biologics","sponsor":"GeneQuantum Healthcare","pharmaFlowCategory":"D","amount":"$28.3 million","upfrontCash":"Undisclosed","newsHeadline":"Thousand Oaks Biologics and GeneQuantum Healthcare Signed A Strategic Partnership Agreement for ADC Drug Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"ClearPoint Neuro","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Discovery Platform"},{"orgOrder":0,"company":"ElevateBio","sponsor":"AyurMaya Capital Management Fund","pharmaFlowCategory":"D","amount":"$401.0 million","upfrontCash":"Undisclosed","newsHeadline":"ElevateBio Announces $401 Million Series D Financing to Further Accelerate Growth","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery Platform"},{"orgOrder":0,"company":"AstriVax","sponsor":"VLAIO","pharmaFlowCategory":"D","amount":"$2.6 million","upfrontCash":"Undisclosed","newsHeadline":"AstriVax Awarded \u20ac2.5 Million Grant to Advance Innovative Vaccine Platform","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"BELGIUM","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Discovery Platform"},{"orgOrder":0,"company":"XtalPi","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$250 million","upfrontCash":"Undisclosed","newsHeadline":"XtalPi Announces Collaboration with Lilly, Using AI + Robotics to Uncover First-in-class Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"aVaxziPen","sponsor":"CEPI","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Needle-free Vaccine Delivery Platform Aims To End Frozen Storage Needs And Improve Access","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Merdury Pharmaceutical","sponsor":"BIOKEY","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"TAIWAN","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Iktos","sponsor":"Curreio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Curreio and Iktos Announce Collaboration in New Drug Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"AbCellera","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Acuitas","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bayer Strengthens Gene Therapy Portfolio with Lipid Nanoparticle Technology from Acuitas Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Undisclosed"},{"orgOrder":0,"company":"Elsie Biotechnologies","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Elsie Biotechnologies Announces Collaboration with GSK to Accelerate Oligonucleotide Discovery Technologies","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Doer Biologics Announces License Agreement with BioNTech","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$1,316.0 million","upfrontCash":"$16.0 million","newsHeadline":"Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Preclinical"},{"orgOrder":0,"company":"Pioneering Medicines","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$800.0 million","upfrontCash":"$100.0 million","newsHeadline":"Flagship Pioneering and Pfizer Partner to Accelerate Development of Innovative Medicines Targeting Unmet Needs","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Chroma Medicine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"$749.9 million","upfrontCash":"$21.2 million","newsHeadline":"Astellas and PeptiDream Enter into Research Collaboration and License Agreement to Discover Novel Targeted Protein Degraders","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Discovery"},{"orgOrder":0,"company":"InstaDeep","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"$548.6 million","upfrontCash":"$548.6 million","newsHeadline":"BioNTech Completes Acquisition of InstaDeep","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery Platform"},{"orgOrder":0,"company":"CAS","sponsor":"Molecule.one","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"CAS and Molecule.one Announce a Strategic Collaboration to Accelerate Drug Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Genesis Therapeutics","sponsor":"Andreessen Horowitz","pharmaFlowCategory":"D","amount":"$200.0 million","upfrontCash":"Undisclosed","newsHeadline":"Genesis Therapeutics Closes Oversubscribed $200 Million Series B","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Superluminal Medicines","sponsor":"RA Capital","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"Undisclosed","newsHeadline":"Superluminal Medicines Launches with $33 Million Seed Round to Fuel its Drug Discovery Engine and Pipeline of Small Molecule Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Tentarix Biotherapeutics","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tentarix Biotherapeutics Completes Series B Financing Bringing Total Equity and Upfront Deal Consideration to $132 Million","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Septerna","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$47.5 million","newsHeadline":"Septerna Announces Novel GPCR-targeted Program Acquired by Vertex","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Expands Antibody Discovery Collaboration with BeiGene","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PeptiDream Announces Collaboration and License Agreement with Genentech for the Discovery and Development of Novel Peptide-Radioisotope Drug Conjugates","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Peptide","graph2":"Discovery"},{"orgOrder":0,"company":"BioLoomics","sponsor":"Innovation Endeavors","pharmaFlowCategory":"D","amount":"$8.7 million","upfrontCash":"Undisclosed","newsHeadline":"BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"AbCellera","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Partillion Bioscience","sponsor":"Alloy Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Partillion Bioscience Corporation Announces Seed Financing, Expanded Board, and New Partnership with Alloy Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"$331.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Medicinova","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"MediciNova Receives Gene Therapy Milestone Payment","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Undisclosed"},{"orgOrder":0,"company":"Salipro Biotech","sponsor":"Icosagen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Salipro Biotech and Icosagen Launch Antibody Discovery Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"EpimAb Biotherapeutics","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"$210.0 million","upfrontCash":"Undisclosed","newsHeadline":"EpimAb Biotherapeutics and Almirall Announce Bispecific Antibody License Agreement","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Genentech","pharmaFlowCategory":"D","amount":"$1,026.0 million","upfrontCash":"$26.0 million","newsHeadline":"Sosei Heptares will Receive US$3.75 Million Payment in Multi-Target Partnership","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Announces Strategic Collaboration with GeneQuantum Healthcare to Empower Early Discovery of Next-Generation Bioconjugates","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Cannasoul","sponsor":"Synaptogenix","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Undisclosed"},{"orgOrder":0,"company":"Serina Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Taiho Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Araris Biotech AG Announces Research Collaboration with Taiho Pharmaceutical to Develop Next-Generation ADCs Using Araris\u2019 Proprietary Linker-Conjugation Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Prism Biolab","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$660.0 million","upfrontCash":"Undisclosed","newsHeadline":"PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ShapeTX Expands Strategic Collaboration with Roche with Addition of a New Target","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Preclinical"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Lycia Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Announces Collaboration Agreement with Lycia Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"The Benchmark Company LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IPA Announces Proposed Public Offering of Common Shares","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"IPA Announces Closing of $1.265 Million Public Offering of Common Shares","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nona Biosciences Announces Collaboration with Evive Biotech to Accelerate Antibody Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"X-Chem","sponsor":"Relay Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"X-Chem Announces Achievement of Collaboration Milestone","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Aqemia","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$140.0 million","upfrontCash":"Undisclosed","newsHeadline":"AQEMIA Announces a Major Multi-year Collaboration of $140 Million with Sanofi","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"IPA Announces Pricing of $1.1 Million Public Offering of Common Shares","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Depixus","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Depixus Announces Strategic Collaboration with Daiichi Sankyo to Use MAGNA\u2122 Technology to Accelerate RNA-targeted Drug Discovery","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Anagenex","sponsor":"Nimbus Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Anagenex and Nimbus Announce a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Multiple Indications","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery"},{"orgOrder":0,"company":"Genentech","sponsor":"NVIDIA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Isomorphic Labs","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,237.5 million","upfrontCash":"$37.5 million","newsHeadline":"Isomorphic Labs Announces Strategic Multi-target Research Collaboration with Novartis","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Moonwalk Biosciences","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","amount":"$57.0 million","upfrontCash":"Undisclosed","newsHeadline":"Moonwalk Biosciences Launches with $57 Million in Financing to Advance a New Class of Precision Epigenetic Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Undisclosed","graph2":"Discovery Platform"},{"orgOrder":0,"company":"AbCheck","sponsor":"Ampersand Biomedicines","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ampersand Biomedicines Acquires AbCheck to Accelerate Platform and Product Development","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"CZECH REPUBLIC","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Elsie Biotechnologies","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GSK Exercises Option to License Elsie Biotechnologies\u2019 Discovery Platform to Find and Develop Novel Oligonucleotides","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Discovery Platform"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Study Phase
          filter Product Type

            Active Filter(s):

            Product Type

            Development Status

            Details:

            Through a license agreement, GSK will have the option to utilize Elsie’s discovery platform and P(V) chemistry technologies for its research in oligonucleotide drug discovery.

            Lead Product(s): Undisclosed

            Therapeutic Area: Technology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: GSK

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement February 14, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration aims to discover small molecule therapeutics against three undisclosed targets by using the power of artificial intelligence.

            Lead Product(s): Undisclosed

            Therapeutic Area: Technology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Small molecule

            Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

            Deal Size: $1,237.5 million Upfront Cash: $37.5 million

            Deal Type: Collaboration January 07, 2024

            AS